Friday Furnace

Cue Biopharma reported a Q2 2026 net loss of $153.1 million — versus $8.5 million in the year-ago quarter — driven almost entirely by accounting charges tied to its April 30 license of anti-IgE antibody Ascendant-221. The single largest item was a $90.0 million loss on the issuance of liability-classified warrants to Ascendant Health Sciences, partially offset by a $24.5 million mark-to-market gain on the same instruments. A further $19.7 million of non-cash stock-based compensation and roughly $23 million in transaction and leadership-transition costs pushed G&A to $46.6 million for the quarter. Cash stood at $17.4 million at June 30 before a $50 million private placement, led by Cormorant Asset Management and Columbia Threadneedle, closed on July 13.

CBNK Capital Bancorp, Inc. Turnaround

Capital Bancorp Swaps Auditors Eleven Weeks After Shareholder Ratification

Market cap : at edition (Aug 14, 2026) $617M

Capital Bancorp dismissed Elliott Davis, PLLC as its auditor on August 14, 2026 — roughly eleven weeks after shareholders voted to ratify the firm at the May 28 annual meeting — and replaced it with Crowe LLP. The change follows the company's disclosure of a material weakness in internal controls over financial reporting in its 2025 Annual Report. No disagreements with Elliott Davis were reported, and Crowe already had a pre-existing engagement with Capital Bancorp from valuation work tied to the 2024 IFH acquisition.

ZNTL Zentalis Pharmaceuticals, Inc. Runway Extension

Zentalis Issues $75M Equity Offering Seven Days After Cash Guidance

Market cap : at edition (Aug 14, 2026) $307M

Zentalis Pharmaceuticals entered into an underwriting agreement on August 13 to sell 23 million shares at $3.50 each, generating approximately $75.1 million in net proceeds, closing August 17. The raise came seven days after the company told investors its $174.6 million cash position was "sufficient" to fund operations into late 2027. On the same August 6 earnings call, Zentalis disclosed that the key DENALI Phase 2 trial readout had slipped six months — from year-end 2026 to the first half of 2027 — while quarterly operating losses accelerated to $42.3 million, up from $35.4 million in the prior quarter.

NAMS Newamsterdam Pharma Co N.V. Management Transition

NewAmsterdam COO Exits Without Named Successor at EU Launch Eve

Market cap : at edition (Aug 14, 2026) $3.3B

Douglas Kling left as NewAmsterdam Pharma's Chief Operating Officer on August 14, 2026 — three weeks after the company and partner Menarini received a positive EU regulatory opinion for obicetrapib — with no successor announced. Under a formal Advisor Agreement, Kling will collect $50,000 per month through May 14, 2027 to support the PREVAIL cardiovascular outcomes trial and other clinical programs, while certain service-based equity awards continue vesting. Separately, newly hired VP Controller Robert Gunning took over as Principal Accounting Officer on August 10, replacing Louise Kooij whose April-disclosed departure takes effect August 31.

ACHV Achieve LIFE Sciences, Inc. Serial Equity Issuance

Achieve Adds $150M ATM Four Months After $180M Private Placement

Market cap : at edition (Aug 14, 2026) $687M

Achieve Life Sciences established a $150 million at-the-market equity facility with Jefferies LLC on August 14, 2026, four months after closing a $180 million private placement. The company held $187.3 million in cash and marketable securities as of June 30, meaning the ATM is supplemental rather than a survival measure. The offering follows a year of leadership turnover — including a new CEO, departed CMO, CCO, and Board Chair — and a June 20 FDA Complete Response Letter that pushed the cytisinicline commercial launch to the first half of 2027.

VUZI Vuzix, Corp. Distressed

Vuzix Opens $100M Stock Sale Facility as Cash Burns

Market cap : at edition (Aug 14, 2026) $218M

Vuzix replaced its 2024 at-the-market equity facility with a new $100 million program through Jefferies LLC, at a 3% commission, against a backdrop of roughly $7 million in quarterly net losses on revenues that barely reach $1.4 million per quarter. Operating cash burn hit $5.6 million in Q1 2026 alone, while the company ended 2025 with $21.2 million in cash. The ATM is, in practical terms, the company's primary funding mechanism for ongoing operations.

SES SES AI, Corp. Exchange Compliance

NYSE Halts SES AI Warrant Trading, Begins Delisting

Market cap : at edition (Aug 14, 2026) $212M

The NYSE immediately suspended trading in SES AI's public warrants (SES WS) on August 13, 2026 and commenced delisting proceedings, citing "abnormally low selling price" levels under Section 802.01D. Unlike the stock price non-compliance notice SES AI received just 27 days earlier — which carries a six-month cure period — the warrant action took effect with no cure window. Each warrant carries an $11.50-per-share exercise price, rendering it economically worthless against a Class A stock trading below $1.00. Trading in the Class A common stock itself continues on NYSE under the ticker SES, unaffected by the warrant action.

OPK OPKO Health, Inc. Distressed

OPKO Pledges Royalty Assets for $125 Million at 11.5%

Market cap : at edition (Aug 14, 2026) $1.0B

OPKO Health raised $125 million in additional senior secured notes on August 13, 2026, bearing interest at a minimum of 11.5% — the 3-month SOFR rate subject to a 4% floor, plus 7.5% — under an amendment to an existing note purchase agreement with royalty-finance specialist HCR Injection SPV, LLC. The notes are secured against EirGen Pharma's Pfizer profit-share payments and its royalty interest in mazdutide sales in China under a license with Eli Lilly, with those mazdutide payments capped at $187.5 million. The raise comes as OPKO's full-year 2026 guidance implies an operating loss of roughly $125–180 million on revenues of $560–585 million against total costs and expenses of $710–740 million. Cash on hand stood at $300.8 million as of June 30, 2026, down from $369.1 million at year-end 2025, partly offset by $105.3 million spent repurchasing shares since the buyback program began.

OPTU Optimum Communications, Inc. Listing At Risk

Optimum Communications Receives NYSE Delisting Warning as Stock Stays Below $1

Market cap : at edition (Aug 14, 2026) $227M

Optimum Communications received an NYSE non-compliance notice on August 13, 2026, after its Class A shares traded below $1.00 for 30 consecutive days, giving the company until February 13, 2027 to cure or face delisting proceedings. The notice arrives as the company's main operating subsidiary, CSC Holdings, carries $21.775 billion in net debt at 22.8x leverage with approximately $4.1 billion due in April 2027, and as revenue has declined for seven straight quarters. Management stated the board will consider unspecified "other options" — which under NYSE rules could include a reverse stock split subject to shareholder approval — if the stock price does not recover on its own.

HNRG Hallador Energy Co. Credit Pressure

Hallador Rewrites EBITDA Definition Retroactively for Q2 in Third Credit Amendment

Market cap : at edition (Aug 14, 2026) $743M

Hallador Energy amended its credit agreement on August 11, 2026 — the third change to a facility that is barely five months old — to retroactively expand the EBITDA definition for the quarter just ended, permitting an add-back of up to $10 million for payments received under power purchase agreement exclusivity agreements during Q2 2026. The amendment arrived one day after the company reported a $15.2 million Q2 net loss and negative adjusted EBITDA of $2.9 million, extending a string of losses that included a $9.3 million net loss in Q1. The pattern of successive amendments — covenant ratios widened in June, EBITDA definition expanded in August — maps directly onto two quarters of deteriorating earnings, and raises the question of how much runway remains in the current facility before further renegotiation is required.

ARCC ARES Capital, Corp. Nav Erosion

Ares Capital Secures Below-NAV Share Issuance Authority at Special Meeting

Market cap : at edition (Aug 14, 2026) $14.3B

Shareholders of Ares Capital Corporation voted on August 13, 2026 to authorize the company to issue common stock at prices below its net asset value per share, passing with roughly 77% in favor and 19% opposed. The authorization, capped at 25% of outstanding shares, runs through August 13, 2027. The approval comes as NAV per share has declined from a record $20.01 in September 2025 to $19.35 as of June 30, 2026, and Core EPS of $0.47 sits a penny below the $0.48 quarterly dividend. The vote followed a separate $1.5 billion at-the-market equity program established in April 2026, giving ARCC — the world's largest BDC — two parallel channels for equity issuance.

KLC Kindercare Learning Companies, Inc. Family Controlled Related Party

KinderCare Raises Rent Escalation Cap in Related-Party Lease Covering 545 Sites

Market cap : at edition (Aug 14, 2026) $550M

KinderCare Education LLC restructured the master lease covering all 545 of its operating sites with related-party landlord KCP RE LLC, effective August 11, 2026, raising the cap on future rent increases from 10% to 12.5%. Thirteen sites were simultaneously transferred to a new landlord affiliate, KCP RE II LLC, under a separate lease expiring in 2029. The amendment came the same week the company reported a $298.6 million GAAP net loss for the first half of 2026 and cut its full-year revenue and adjusted EBITDA guidance.

BBBY Neighborhood Intelligence, Inc. Strategic Pivot

Bed Bath & Beyond Becomes Neighborhood Intelligence, Moves to Nasdaq

Market cap : at edition (Aug 14, 2026) $403M

Bed Bath & Beyond, Inc. formally renamed itself Neighborhood Intelligence, Inc. on August 14, 2026 and transferred its listing from the NYSE to Nasdaq, where it now trades under the ticker NXH. The name change, adopted by the board under Delaware law without a stockholder vote, is the capstone of a twelve-month acquisition campaign that added The Container Store, Kirkland's brands, SFV Services, and two pending deals — Fathom Holdings and F9 Brands — to an originally e-commerce retail platform. The company issued $112.6 million in 5% convertible notes to fund the Container Store deal, carries an accumulated deficit of $898.6 million, and burned $50 million in operating cash in the first half of 2026, while reporting Q2 net revenue of $361 million, up 28% year-over-year.

Cue Biopharma Books $153M Loss as Ascendant Warrant Accounting Dominates Q2